Ociperlimab (BGB-A1217)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ociperlimab (BGB-A1217), covering 2025-08-22 to 2025-08-22. Get the full timeline:
Most recent: Clinical Trial Update: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors [Phase 1]